Immunotherapy Archives

Immatics cancer personalized cell therapy

News and Trends 21 Aug 2017

German Biotech Starts Trials with a Personalized Cell Therapy for Multiple Cancers

Immatics will start a first clinical trial to test IMA101, a personalized cell therapy with the potential to treat multiple types of solid tumors. Based in Tübingen, Germany, Immatics has announced today the start of its first clinical trial testing its cell therapy technology aimed at providing personalized treatments for multiple types of solid tumors. The […]

August 21, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Jul 2017

Novartis largely dodged deaths from its CAR-T therapy, but FDA still has safety concerns

Editor’s Note: Novartis did note a death from cerebral hemorrhage in its hearing with the FDA yesterday. With the application review hearing set for tomorrow, the FDA has shared its thoughts on Novartis’ CAR-T candidate. Up front are serious safety concerns. Novartis’ CTL019, or Tisagenlecleucel, wowed the audience at ASH last fall with a stellar 82% […]

July 11, 2017 - 3 minutesmins - By Evelyn Warner

Interview 3 Jul 2017

These Norwegian Biotech Execs are Bringing Back Cancer Vaccines & Oncolytic Viruses

We talked to CEO Øystein Soug and CMO Magnus Jäderberg of Targovax about why the company’s technologies may succeed where others have failed. In 2010, Targovax rose from the ashes of Norsk Hydro Pharma, the discontinued therapeutic development arm of the conglomerate. The Oslo-based biotech is taking a stand against tough-to-treat cancers like that of […]

July 3, 2017 - 8 minutesmins - By Evelyn Warner

News and Trends 30 Jun 2017

Belgian Biotech Starts Phase Ib with an off-the-shelf mRNA Therapy for Melanoma

eTheRNA has started a Phase Ib trial in patients with melanoma to test a cancer immunotherapy based on off-the-shelf mRNA technology. eTheRNA is one of the few companies working in mRNA therapies that are running clinical trials. The Belgian biotech has announced the start of a Phase Ib trial with its candidate TriMix-MEL, also called ECI-006, in patients […]

June 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Araclon Biotech Alzheimers Vaccine Spain Zaragoza

News and Trends 27 Jun 2017

A Spanish Vaccine to fight Alzheimer’s Before Symptoms Appear enters Phase II

Araclon Biotech will advance to Phase II with an Alzheimer’s vaccine that could succeed where many others have failed before. Araclon Biotech, in Zaragoza, Spain, has announced today the approval from the Spanish Agency of Medicines and Medical Devices to start a Phase II trial testing its Alzheimer’s vaccine in 120 patients in 22 centers across Europe. The […]

June 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 20 Jun 2017

“We’re at a second revolution in cancer therapy” – Experts discuss the Future of Oncology at Refresh

A panel of experts in immuno-oncology discussed the challenges and opportunities to develop therapies that can effectively fight cancer. “I think right now we’re at a second revolution in cancer therapy, which surprisingly is not necessarily driven by technology but perspective, and how we look at cancer,” said Masoud Tavazoie, CEO of Rgenix. His company, based in New York, […]

June 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Jun 2017

Norwegian Biotech Hits €21M in Private Placement for its Immunotherapies

Targovax has raised €21M (NOK200M) in a private placement, which the biotech will use to fund data read-outs from clinical trials and CMC development. Targovax, based in Oslo, is developing a number of immunotherapies for treatment-resistant tumors. The biotech’s pipeline is based on its two platforms, ONCOS, an oncolytic virus, which is being developed to treat melanoma, […]

June 12, 2017 - 2 minutesmins - By Melanie De Almeida

Interview 12 Jun 2017

This Italian Academic-turned-CEO also Launched 7 Cancer Drugs at GSK

Paolo Paoletti might have been forced to reconsider his career as a professor in medicine, but academia’s loss was biopharma’s gain! Before becoming CEO of one of London’s most exciting biotechs, GammaDelta Therapeutics, Paolo Paoletti had a long run through the corporate ranks of pharma. He was coaxed out of academic medicine to join Eli […]

June 12, 2017 - 9 minutesmins - By Evelyn Warner

News and Trends 6 Jun 2017

French Biotech Strikes Deal with Novo Nordisk for New Cancer Drug

Novo Nordisk has handed over its anti-cancer antibody to Innate Pharma in a new deal that could earn the diabetes specialist up to €370M in milestones. The immuno-oncology biotech Innate Pharma has in-licensed a new clinical-stage antibody candidate from Novo Nordisk to reinforce its position in the crowded space. In exchange for its anti-C5aR antibody, IPH5401, […]

June 6, 2017 - 2 minutesmins - By Melanie De Almeida

Oryx glioblastoma ParvOryx combination 1

News and Trends 23 May 2017

German Biotech Tops Up its Oncolytic Virus with Immuno-Oncology Drugs

Oryx has reported good clinical data on the combination of its oncolytic virus with immuno-oncology drugs, convincing the biotech to start clinical trials. Based in Munich, Oryx is developing cancer immunotherapies for a number of solid tumors consisting of oncolytic viruses and peptide vaccines. The company just announced positive clinical data for 16 patients treated under compassionate use […]

May 23, 2017 - 2 minutesmins - By Melanie De Almeida

Interview 22 May 2017

Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer

Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing and discusses how the dutch biotech ecosystem has evolved. Arthur Lahr has been part of the Dutch biotech scene for over 15 years now. The former Chief Strategy Officer of Crucell, which was sold to J&J in 2011, is now […]

May 22, 2017 - 7 minutesmins - By Clara Rodríguez Fernández

Noxxon Merck checkpoint inhibitor combination

News and Trends 16 May 2017

Berlin Biotech Advances its Cancer Drug in a New Trial with Keytruda

Noxxon Pharma has teamed up with the NCT in Heidelberg to conduct a Phase I/II trial combining its lead NOX-A12 with checkpoint inhibitor Keytruda. Based in Berlin, Noxxon is yet another biotech looking to bolster the success of checkpoint inhibitors by combining them with its ‘next-generation’ immuno-oncology candidates. The company partnered up with Merck & Co. […]

May 16, 2017 - 2 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

German Biotech Starts Trials with a Personalized Cell Therapy for Multiple Cancers

Novartis largely dodged deaths from its CAR-T therapy, but FDA still has safety concerns

These Norwegian Biotech Execs are Bringing Back Cancer Vaccines & Oncolytic Viruses

Belgian Biotech Starts Phase Ib with an off-the-shelf mRNA Therapy for Melanoma

A Spanish Vaccine to fight Alzheimer’s Before Symptoms Appear enters Phase II

“We’re at a second revolution in cancer therapy” – Experts discuss the Future of Oncology at Refresh

Norwegian Biotech Hits €21M in Private Placement for its Immunotherapies

This Italian Academic-turned-CEO also Launched 7 Cancer Drugs at GSK

French Biotech Strikes Deal with Novo Nordisk for New Cancer Drug

German Biotech Tops Up its Oncolytic Virus with Immuno-Oncology Drugs

Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer

Berlin Biotech Advances its Cancer Drug in a New Trial with Keytruda

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!